BioAge Labs Inc(BIOA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 14 at 7:30 PM ET (Korea 9/15 08:30)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -2.39 | Insider Own | 32.61% | Shs Outstand | 45.8M | Perf Week | -11.57% |
| Market Cap | 0.39B | Forward P/E | - | EPS next Y | 10.59% | Insider Trans | -0.47% | Shs Float | 30.9M | Perf Month | -18.7% |
| Enterprise Value | 0.07B | PEG | - | EPS next Q | -0.62 | Inst Own | 60.94% | Short Float | 8.8% | Perf Quarter | -52.99% |
| Income | -0.09B | P/S | 37.57 | EPS this Y | -8.51% | Inst Trans | 9.71% | Short Ratio | 3.12 | Perf Half Y | -54.7% |
| Sales | 0.01B | P/B | 1.04 | EPS next 5Y | -4.63% | ROA | -26.27% | Short Interest | 2.72M | Perf YTD | -35.9% |
| Book/sh | 8.19 | P/C | 1.22 | EPS past 3/5Y | -24.49% - | ROE | -28.21% | 52W High | -67.33% ($25.95) | Perf Year | 76.67% |
| Cash/sh | 6.94 | P/FCF | - | Sales past 3/5Y | - | ROIC | -25.05% | 52W Low | 81.2% ($4.68) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -6.76% | Gross Margin | 97.58% | Volatility(W/M) | 4.89% 5.49% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 7.07 | Sales Y/Y TTM | 168.06% | Oper. Margin | -1026.28% | ATR (14) | 0.77 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 17.19 | EPS Q/Q | 3.24% | Profit Margin | -912.25% | RSI (14) | 29.18 | Recom | 1.44 |
| Dividend Gr. 3/5Y | - | Current Ratio | 17.19 | Sales Q/Q | 1.62% | SMA20 | -11.6% ($9.59) | Beta | 1 | Target Price | $35.62 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/8/5 | SMA50 | -43.11% ($14.91) | Rel Volume | 0.65 | Prev Close | $8.49 |
| Employees | 62 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | 4.5% 63.65% | SMA200 | -49.92% ($16.93) | Avg Volume(3M) | 0.87M | Price | $8.48 |
| IPO | 2024/9/26 | Option/Short | Yes/Yes | Trades | 7539 | Volume | 563,388 | Change | -0.12% |
Company
BIOA is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 BioAge Labs (BIOA) is a clinical-stage biopharmaceutical company developing therapeutics for obesity and metabolic diseases, targeting the biology of human aging. Leveraging its aging data platform, the company identifies novel drug candidates and is advancing a pipeline that includes a lead obesity drug candidate, alongside collaborative research with global pharmaceutical companies.
Over the past 1 year, on the lower side
67% below its 1-year high.
BIOA has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -8.5% this year.
Tap to view numbers
The stock looks undervalued
Trading at - times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 60.9%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
XPH 0.01%
PILL 0.01%
PTH 0.01%
DWAS 0.00%
IWC 0.00%It ranks #4 in the industry
Based on market cap of $389M.
BIOA $389M PER -
TAK $59B PER -
TEVA $45B PER 64.5
HLN $41B PER 19.3
FAQ
What kind of company is BIOA?
BIOA belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of BIOA?
The market cap of BIOA is approximately $389M, ranking 3,444 within its sector.
What is the 52-week high and low for BIOA?
BIOA has recorded a 52-week high of $25.95 and a low of $4.68.
